Anifrolumab
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Pressure score
64
Momentum score
5
Why This Matters
Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.
Competitive Assessment
- Threat type
- regulatory competitor
- Development stage
- Stage unknown
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Moderate share risk if competitor advances before the signal sponsor establishes label leadership.
Strategic Action
Align with signal posture: monitor. Monitor regulatory competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Roche's Anifrolumab directly references the same indication focus (Immunology · Systemic Lupus Erythematosus) as this signal.
Source: Roche
View source documentRelated Signal
AstraZeneca's Anifrolumab Study for Systemic Lupus Erythematosus Underway
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 2
Roche
4 competitive findings
Top program: Anifrolumab
- Pressure
- 65
- Momentum
- 5
- Threat
- regulatory competitor
- Stage
- Stage unknown
65RocheMediumAnifrolumab·Stage unknown
Bristol Myers Squibb
1 competitive finding
Top program: Anifrolumab
- Pressure
- 52
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
52Bristol Myers SquibbMediumAnifrolumab·Stage unknown